Hao Kelly, Paik Andrew J, Han Lauren H, Makary Mina S
College of Medicine, The Ohio State University, Columbus, OH 43210, United States.
Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, United States.
World J Radiol. 2024 Oct 28;16(10):512-527. doi: 10.4329/wjr.v16.i10.512.
As the third leading cause of cancer-related deaths worldwide, hepatocellular carcinoma (HCC) represents a significant global health challenge. This paper provides an introduction and comprehensive review of transarterial radioembolization (TARE) with Yttrium-90 (Y90), a widely performed transcatheter procedure for HCC patients who are not suitable candidates for surgery. TARE involves the targeted delivery of radioactive microspheres to liver tumors, offering a promising treatment option for managing HCC across various stages of the disease. By evaluating Y90 TARE outcomes across early, intermediate, and advanced stages of HCC, the review aims to present a thorough understanding of its efficacy and safety. Additionally, this paper highlights future research directions focusing on the potential of combination therapies with systemic and immunotherapies, as well as personalized treatments. The exploration of these innovative approaches aims to improve treatment outcomes, reduce adverse events, and provide new therapeutic opportunities for HCC patients. The review underscores the importance of ongoing research and clinical trials to optimize TARE further and integrate it into comprehensive HCC treatment paradigms.
作为全球癌症相关死亡的第三大主要原因，肝细胞癌（HCC）是一项重大的全球健康挑战。本文对钇-90（Y90）经动脉放射性栓塞术（TARE）进行了介绍和全面综述，这是一种广泛应用于不适合手术的HCC患者的经导管操作。TARE涉及将放射性微球靶向递送至肝脏肿瘤，为在疾病各个阶段管理HCC提供了一种有前景的治疗选择。通过评估Y90 TARE在HCC早期、中期和晚期的疗效，本综述旨在全面了解其有效性和安全性。此外，本文强调了未来的研究方向，重点是与全身治疗和免疫治疗联合疗法的潜力以及个性化治疗。对这些创新方法的探索旨在改善治疗效果、减少不良事件，并为HCC患者提供新的治疗机会。该综述强调了持续研究和临床试验对于进一步优化TARE并将其纳入全面的HCC治疗模式的重要性。
